Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 5, 2008, Pages 607-614

  Tassiopoulos, Katherine ^a,b   Williams, Paige L ^a,b   Seage III, George R ^a,b   Crain, Marilyn ^c   Oleske, James ^d   Farley, John ^e  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Dyslipidemia; HIV; Pediatric; Protease inhibitors

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERINATAL INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT REFUSAL; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 41149133309     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181648e16     Document Type: Article

References (36)

1. Gortmaker S, Hughes M, Cervia J, et al, for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
2. Gona P, Van Dyke R, Williams P, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300.
3. Storm D, Boland M, Gortmaker S, et al, for the Pediatric AIDS Clinical Trials Group Protocol 219 Study Team. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics. 2005;115:e173-e182.
4. Lee G, Gortmaker S, McIntosh K, et al, for the Pediatric AIDS Clinical Trials Group Protocol 219C Team. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics. 2006;117:273-283.
5. Buchacz K, Rogol A, Lindsey J, et al, for the Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr. 2003;33:56-65.
6. Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr. 2003;32:482-489.
7. Bitnun A, Sochett E, Dick P, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2005;90:168-174.
8. Sanchez Torres A, Munoz Muniz R, Madero R, et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164:271-276.
9. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naïve HIV-infected children. AIDS. 2003;17:1319-1327.
10. Melvin A, Lennon S, Mohan K, et al. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses. 2001;17:1117-1123.
11. Farley J, Gona P, Crain M, et al, for the Pediatric AIDS Clinical Trials Group Study 219C Team. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr. 2005;38:480-487.
12. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:56-62.
13. Temple M, Koranyi K, Nahata M. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors. Ann Pharmacother. 2003;37:1214-1218.
14. Solorzano Santos F, Gochicoa Rangel L, Palacios Saucedo G, et al. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res. 2006;37:129-132.
15. Cheseaux J, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr. 2002;30:288-293.
16. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:161-168.
17. Rhoads M, Smith C, Tudor-Williams G, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med. 2006;7:16-24.
18. Carter R, Wiener J, Abrams E, et al, for the Perinatal AIDS Collaborative Transmission Study-HIV Follow-up After Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE Cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr. 2006;41:453-460.
19. Lenhard J, Croom D, Weiel J, et al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625-2629.
20. Zhang G, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab. 1999;84:4274-4277.
21. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol. 2001;12:313-319.
22. Newman W, Freedman D, Voors A, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med. 1986;314:138-144.
23. American Academy of Pediatrics. Cardiovascular risk reduction in high risk populations. Pediatrics. 2007;119:618-621.
24. McCrindle B, Urbina E, Dennison B, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association, Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-1967.
25. Dubé M, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
26. The Expert Panel of the National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
27. McComsey G, Bhumbra N, Ma J, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275-e281.
28. Vigano A, Aldrovandi G, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10:917-924.
29. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
30. Macassa E, Delaugerre C, Teglas J, et al. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J. 2006;25:809-814.
31. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2006:1-126. Available at: http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. Accessed June 29, 2007.
32. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
33. Fichtenbaum C, Gerber J, Rosenkranz S, et al, and the NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
34. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendations statement. Pediatrics. 2007;120:e215-e219.
35. Craig S, Amin R, Russell D, et al. Blood cholesterol screening: influence of fasting state on cholesterol results and management decisions. J Gen Intern Med. 2000;15:395-399.
36. McComsey G, Leonard E. Metabolic complications of HIV therapy in children. AIDS. 2004;18:1753-1768.